glp-1 obesity drugs pipeline Transforming obesity: The advancement of multi-receptor drugs: Cell GLP-1 Agonists For Obesity In

Epidemiological evidence demonstrates a strong association between obesity and KOA, highlighting shared pathogenic mechanisms

Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review. Cureus , vol

Similarly, in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model, GLP-1 analogues were reported to protect the brain from MPTP-induced pathological effects, such as movement disorders, increased levels of -synuclein, chronic inflammation in the brain, loss of dopaminergic neurons, oxidative stress, and expression of growth factors (65)

The antiallodynic effect was entirely blocked by the microglial inhibitor minocycline, -endorphin antiserum, or the opioid receptor antagonist naloxone [24]

Due to their preclinical testing and lack of comparison with other dual receptor agonists such as tirzepatide, further studies are needed to determine whether the effects of these unimolecular compounds are superior to those of clinically tested drugs